TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Abstract

TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

Keywords: TP53; acute myeloid leukemia (AML); cutoff; excess blasts; myelodysplastic syndrome (MDS); p53.